Our findings from an exploratory, small-scale, prospective cohort study of EGFR-mutant patients with NSCLC support the importance of single-cell-level molecular analysis, including an EMT signature, to investigate the dynamics of disease progression and predict the drug response. This evidence concerns the gene EGFR and non-small cell lung carcinoma.